Drug Trial Radar · NCT04481139
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
504
Actual
Start
Oct 14, 2020
Primary completion
Nov 15, 2022
Study completion May 12, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.
Conditions
- Ankylosing Spondylitis
Interventions
SHR0302Drug
SHR0302, oral, once daily
SHR0302 placeboDrug
SHR0302 placebo, oral, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 12.Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhanguo Li
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.